Modification of human erythrocyte pyruvate kinase by an active site-directed reagent: bromopyruvate

J Enzyme Inhib. 2001 Nov;16(5):457-64. doi: 10.1080/14756360109162395.

Abstract

Human erythrocyte pyruvate kinase was modified with bromopyruvate and the kinetic behavior of the modified enzyme was investigated. When the enzyme was modified with bromopyruvate in the absence of adenosine-5'-diphosphate, phosphoenolpyruvate or fructose-1,6-diphosphate the inactivation followed a pseudo first-order kinetics. The inactivation rate constant, ks, was 1.84 +/- 0.15 min(-1). Kd of the bromopyruvate-enzyme complex was 0.14 +/- 0.03 mM. The presence of adenosine-5'-diphosphate, phosphoenolpyruvate or fructose-1,6-diphosphate in the modification medium or the presence of fructose-1,6-diphosphate in the assay medium resulted in deviation of the inactivation kinetics from pseudo first-order. Phosphoenolpyruvate was better than adenosine-5'-diphosphate for protection against bromopyruvate modification whereas fructose-1,6-diphosphate was ineffective. The modified enzyme showed negative cooperativity in the presence of fructose-1,6-diphosphate whereas in the absence of it no activity was detected.

MeSH terms

  • Adenosine Diphosphate / pharmacology
  • Anemia, Hemolytic, Congenital Nonspherocytic / enzymology
  • Binding Sites
  • Enzyme Inhibitors / pharmacology
  • Erythrocytes / enzymology*
  • Fructosediphosphates / pharmacology
  • Humans
  • Kinetics
  • Phosphoenolpyruvate / pharmacology
  • Pyruvate Kinase / chemistry*
  • Pyruvate Kinase / drug effects
  • Pyruvate Kinase / metabolism*
  • Pyruvates / pharmacology
  • Structure-Activity Relationship

Substances

  • Enzyme Inhibitors
  • Fructosediphosphates
  • Pyruvates
  • Adenosine Diphosphate
  • bromopyruvate
  • Phosphoenolpyruvate
  • Pyruvate Kinase
  • fructose-1,6-diphosphate